2-[4-(pyrazoL-4-YYYYYYACACACAC1-1-yl]-3-pyraziazine and propproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropproppropprop
BADESCU Valentina O,CAMP Anne Marie,CLARK Barry Peter,COHEN Michael Philip,FILLA Sandra Ann,GALLAGHER Peter Thaddeus,HELLMAN Sarah Lynne,MAZANETZ Michael Philip,PINEIRO-NUNEZ Marta Maria,SCHAUS John M
申请号：
CY121101219
公开号：
CY1113457T1
申请日:
2012.12.13
申请国别(地区):
CY
年份:
2016
代理人:
摘要：
Η παρούσα εφεύρεση παρέχει επιλεκτικές ενώσεις ανταγωνιστή του υποδοχέα 5-ΗΤ7 του Τύπου I και τη χρησιμοποίηση τους στη θεραπευτική αγωγή της ημικρανίας, του επίμονου πόνου, και του άγχους: όπου τα Α και Β είναι το καθένα ανεξαρτήτως C(H)= ή Ν=, υπό τον όρο ότι τουλάχιστον ένα από τα Α και Β είναι Ν=, το n είναι 1 -3, το m είναι 0-3, και τα R14 είναι όπως ορίζονται στην παρούσα.This invention provides selective competitive compounds of Type I 5-HT7 receptor and their use in the treatment of migraine,of persistent pain,and stress: where A and B are each C(H)= or N=；provided that at least one of the A and B is N=,n is 1-3, m is 0-3, and R14 is as defined in this.
